Updated Mar 23, 2026 by Toho Holdings
Toho Holdings reported a 3.2% year-on-year decline in net sales to 595,962 million yen and a 28.6% drop in operating income to 5,458 million yen for the first half of fiscal year 2018.
The dispensing pharmacy business was a key growth driver, with net sales increasing 2.2% to 48,204 million yen and segment income surging 590.1% to 1,305 million yen.
The company's core pharmaceutical wholesaling segment experienced a 3.6% decline in net sales, totaling 570,639 million yen, largely due to a shrinking prescription market and reduced demand for hepatitis C drugs.
Despite the overall decline in profitability, management maintained its full-year earnings projections as originally announced in May 2017.
Strategic efforts remain focused on the expansion of the generic drug brand KYOSOMIRAI PHARMA and the deployment of value-added support systems for medical institutions.
As of September 30, 2017, the company reported total assets of 633,584 million yen and a shareholder’s equity ratio of 30.4%.
Toho Holdings reported a 3.2% year-on-year decline in net sales to 595,962 million yen and a 28.6% drop in operating income to 5,458 million yen for the first half of fiscal year 2018.
The dispensing pharmacy business was a key growth driver, with net sales increasing 2.2% to 48,204 million yen and segment income surging 590.1% to 1,305 million yen.
The company's core pharmaceutical wholesaling segment experienced a 3.6% decline in net sales, totaling 570,639 million yen, largely due to a shrinking prescription market and reduced demand for hepatitis C drugs.
Despite the overall decline in profitability, management maintained its full-year earnings projections as originally announced in May 2017.
Strategic efforts remain focused on the expansion of the generic drug brand KYOSOMIRAI PHARMA and the deployment of value-added support systems for medical institutions.
As of September 30, 2017, the company reported total assets of 633,584 million yen and a shareholder’s equity ratio of 30.4%.